News
Analyst commentary was mixed. Citi raised its target to $400 from $385; Baird to $385 from $381; Wells Fargo to $400 from $375; Loop Capital to $400 from $365; KeyBanc to $425 from $405; Deutsche Bank to $375 from $371; Piper Sandler to $325 from $319. The FactSet mean price target stands at $380.90, with an average rating of buy or overweight. BNP...
29/04/2026 | Cadence Design Systems, Inc.
Q2 2026 guidance cites revenue of $1.555 billion–$1.595 billion and non‑GAAP EPS of $2.02–$2.08. Days sales outstanding remained stable at 67 days. Cadence highlighted strategic collaborations with Google to optimize its ChipStack AI super‑agent and partnerships with NVIDIA to expand AI and robotics capabilities.
29/04/2026 | Cadence Design Systems, Inc.
Cadence raised its fiscal‑2026 revenue outlook to $6.125 billion–$6.225 billion, a 17% YoY increase, but trimmed adjusted diluted earnings per share to $7.85–$7.95 from the previously guided $8.05–$8.15. GAAP diluted net income per share is now projected at $4.39–$4.49. Operating margin guidance was lowered to 27.5–28.5% GAAP and 43.5–44.5% non‑GAA...
29/04/2026 | Cadence Design Systems, Inc.
Cadence Design Systems (CDNS) reported first‑quarter 2026 results on March 28 2026 that surpassed consensus estimates. Revenue of $1.474 billion represented an 18‑19% year‑over‑year increase, with a GAAP operating margin of 29.3% and a non‑GAAP margin of 44.7%. Net income per share on a non‑GAAP basis was $1.96. Bookings rose 21.4% YoY to $1.49 bil...
29/04/2026 | Cadence Design Systems, Inc.
Crinetics Pharmaceuticals (CRNX) received European Commission approval for PALSONIFY (paltusotine) on 27 member states and 3 EEA countries, making it the first once‑daily oral therapy for adult acromegaly in the EU. Approval was grounded in two Phase 3 studies that showed rapid onset, reliable biochemical control of IGF‑1, sustained efficacy and no...
29/04/2026 | Crinetics Pharmaceuticals, Inc.
Crinetics’ pipeline remains extensive, featuring atumelnant for congenital adrenal hyperplasia and ACTH‑dependent Cushing’s syndrome, as well as candidates targeting neuroendocrine tumors, Graves disease, polycystic kidney disease and GPCR‑targeted oncology indications. The European Commission approval of PALSONIFY is expected to strengthen the com...
29/04/2026 | Crinetics Pharmaceuticals, Inc.
Match Group has invested $100 million in the dating platform Sniffies, acquiring a significant minority ownership stake. The deal includes an option for Match to acquire the remaining equity in the future, mirroring the company’s earlier approach with Hinge (initial investment in 2017, full acquisition in 2018). Sniffies, which competes with Grindr...
29/04/2026 | Match Group, Inc.
Price targets have been reset from CA$6.50 to CA$5.50 on kneat.com, while one valuation framework still centers on a fair value of CA$5.70. Analysts' views on the stock's attractiveness at current levels are mixed, with some maintaining bullish stances despite the revised valuation inputs. The narrative around Kneat.com's business story and forecas...
24/04/2026 | kneat.com, inc.
The current analyst consensus for Kneat.com (KSI.TO) stock is centered around a fair value of CA$5.70. Analysts such as CIBC and Stifel maintain Buy and Outperformer ratings alongside their revised price targets of CA$5.50, indicating that the core equity story remains intact despite the revised valuation inputs. The cluster of targets around CA$5....
24/04/2026 | kneat.com, inc.
Analysts note that the company’s solid financial profile, coupled with a favorable valuation and a positive earnings trajectory, positions Hugo Boss as a potential long‑term appreciation play for investors. The firm’s ability to outperform in a declining sector underscores its resilience, but investors should continue to monitor its progress, espec...
24/04/2026 | Hugo Boss AG